Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

Ramalingam, SS; Vansteenkiste, J; Planchard, D; Cho, BC; Gray, JE; Ohe, Y; Zhou, C; Reungwetwattana, T; Cheng, Y; Chewaskulyong, B; Shah, R; Cobo, M; Lee, KH; Cheema, P; Tiseo, M; John, T; Lin, MC; Imamura, F; Kurata, T; Todd, A; Hodge, R; Saggese, M; Rukazenkov, Y; Soria, JC; N – 2020 – 10.1056/NEJMoa1913662 – The New England Journal of Medicine